Literature DB >> 22538855

Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation.

Renee J Robb1, Katie E Lineburg, Rachel D Kuns, Yana A Wilson, Neil C Raffelt, Stuart D Olver, Antiopi Varelias, Kylie A Alexander, Bianca E Teal, Tim Sparwasser, Gunter J Hammerling, Kate A Markey, Motoko Koyama, Andrew D Clouston, Christian R Engwerda, Geoffrey R Hill, Kelli P A MacDonald.   

Abstract

FoxP3(+) confers suppressive properties and is confined to regulatory T cells (T(reg)) that potently inhibit autoreactive immune responses. In the transplant setting, natural CD4(+) T(reg) are critical in controlling alloreactivity and the establishment of tolerance. We now identify an important CD8(+) population of FoxP3(+) T(reg) that convert from CD8(+) conventional donor T cells after allogeneic but not syngeneic bone marrow transplantation. These CD8(+) T(reg) undergo conversion in the mesenteric lymph nodes under the influence of recipient dendritic cells and TGF-β. Importantly, this population is as important for protection from GVHD as the well-studied natural CD4(+)FoxP3(+) population and is more potent in exerting class I-restricted and antigen-specific suppression in vitro and in vivo. Critically, CD8(+)FoxP3(+) T(reg) are exquisitely sensitive to inhibition by cyclosporine but can be massively and specifically expanded in vivo to prevent GVHD by coadministering rapamycin and IL-2 antibody complexes. CD8(+)FoxP3(+) T(reg) thus represent a new regulatory population with considerable potential to preferentially subvert MHC class I-restricted T-cell responses after bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538855     DOI: 10.1182/blood-2011-12-396119

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  58 in total

1.  HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Authors:  Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

2.  GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.

Authors:  Mark D Bunting; Antiopi Varelias; Fernando Souza-Fonseca-Guimaraes; Iona S Schuster; Katie E Lineburg; Rachel D Kuns; Peter Fleming; Kelly R Locke; Nicholas D Huntington; Bruce R Blazar; Steven W Lane; Siok-Keen Tey; Kelli P A MacDonald; Mark J Smyth; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Blood       Date:  2016-12-07       Impact factor: 22.113

3.  The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.

Authors:  Kyoung Woon Kim; Byung Ha Chung; Bo-Mi Kim; Mi-La Cho; Chul Woo Yang
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

4.  Pregnancy-induced maternal regulatory T cells, bona fide memory or maintenance by antigenic reminder from fetal cell microchimerism?

Authors:  Jeremy M Kinder; Tony T Jiang; Dayna R Clark; Vandana Chaturvedi; Lijun Xin; James M Ertelt; Sing Sing Way
Journal:  Chimerism       Date:  2014-02-19

Review 5.  Diabetes tolerogenic vaccines targeting antigen-specific inflammation.

Authors:  Shuang Geng; Huiyuan Zhang; Xian Zhou; Yue He; Xiaoqian Zhang; Xiaoping Xie; Chaofan Li; Zhonghuai He; Qingling Yu; Yiwei Zhong; Douglas B Lowrie; Guoxing Zheng; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.

Authors:  Kelli P A MacDonald; Laetitia Le Texier; Ping Zhang; Helen Morris; Rachel D Kuns; Katie E Lineburg; Lucie Leveque; Alistair L Don; Kate A Markey; Slavica Vuckovic; Frederik O Bagger; Glen M Boyle; Bruce R Blazar; Geoffrey R Hill
Journal:  J Immunol       Date:  2014-02-28       Impact factor: 5.422

Review 8.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

9.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

Review 10.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.